

In the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application:

Claim 1 (Currently Amended) A method of ~~selectively inhibiting reuptake of norepinephrine~~ treating an individual suffering from peripheral neuropathy, the method comprising the step of administering to the individual a therapeutically effective amount of a composition ~~to an individual, the composition~~ comprising a compound having a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 5000.

Claim 2 (Original) The method of claim 1 wherein said composition is administered in an amount of about 0.1 to about 10 mg/day.

Claim 3 (Original) The method of claim 2 wherein said composition is administered in an amount of about 0.5 to about 8 mg/day.

Claim 4 (Original) The method of claim 3 wherein said composition is administered in an amount of about 0.5 to about 5 mg/day.

Claim 5 (Original) The method of claim 4 wherein said composition is administered in an amount of about 0.5 to about 2.5 mg/day.

Claim 6 (Original) The method of claim 5 wherein said composition is administered in an amount of about 0.5 to about 0.9 mg/day.

Claim 7 (Original) The method of claim 6 wherein said composition is administered in an amount of about 0.5 to about 0.8 mg/day.

Claim 8 (Original) The method of claim 7 wherein said composition is administered in an amount of about 0.5 to about 0.75 mg/day.

Claim 9 (Original) The method of claim 1 wherein said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.

Claim 10 (Original) The method of claim 9 wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

Claim 11 (Original) The method of claim 10 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim 12 (Original) The method of claim 9 wherein said composition is parenterally administered subcutaneously, intraveously, or intramuscularly.

Claim 13 (Original) The method of claim 1 wherein said compound comprises an optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, said compound being substantially free of (R,R) reboxetine.

Claim 14 (Original) The method of claim 13 wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

Claim 15 (Original) The method of claim 13 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claim 16 (Original) The method of claim 15 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt.% of (S,S) reboxetine and less than about 3 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claim 17 (Original) The method of claim 16 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt.% of (S,S) reboxetine and less than about 1 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claims 18-31 (Cancelled).

Claim 32 (Original) The method of claim 1 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 10,000.

Claim 33 (Original) The method of claim 32 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 12,000.

Claim 34 (Original) The method of claim 33 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 25,000.

Claim 35 (Original) The method of claim 34 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 50,000.

Claim 36 (Original) The method of claim 35 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 75,000.

Claim 37 (Original) The method of claim 36 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 100,000.

Claim 38 (Currently Amended) A method of ~~treating a human suffering from a condition, or preventing said condition, wherein inhibiting reuptake of norepinephrine provides a benefit,~~ preventing an individual from having peripheral neuropathy, the method comprising the step of administering to the individual a therapeutically effective amount of a composition comprising a compound having a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 5000.

Claim 39 (Currently Amended) A method of ~~treating a human suffering from a condition, or preventing said condition, wherein inhibiting reuptake of norepinephrine provides a benefit,~~ an individual suffering from peripheral neuropathy while diminishing adverse side effects, the method comprising the step of administering to the individual a total dose of about 0.1 to about 10 mg/day of an optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, ~~to an individual,~~ said optically pure (S,S) reboxetine being substantially free of (R,R) reboxetine.

Claim 40 (Original) The method of claim 39 wherein said adverse side effects comprise dizziness, insomnia, lightheadedness, changes in blood pressure, sweating, gastrointestinal disturbances, sexual dysfunction in males, anticholinergic-like effects, and side effects with drug-drug interactions.

Claims 41-53 (Canceled).